Scarica l'app Stockscreener
5.73
0.00%
0.00
Precedente Chiudi:
$5.73
Aprire:
$5.7
Volume 24 ore:
84,152
Relative Volume:
0.14
Capitalizzazione di mercato:
$38.50M
Reddito:
$500.00K
Utile/perdita netta:
$-7.88M
Rapporto P/E:
-3.3825
EPS:
-1.694
Flusso di cassa netto:
$-5.49M
1 W Prestazione:
-21.40%
1M Prestazione:
+54.45%
6M Prestazione:
-35.11%
1 anno Prestazione:
-68.38%
Intervallo 1D:
$5.63
$6.17
Intervallo di 1 settimana:
$5.145
$6.8938
Portata 52W:
$3.1006
$22.99
Exicure Inc Stock (XCUR) Company Profile
Nome
Exicure Inc
Settore
Industria
Telefono
847-673-1707
Indirizzo
2430 N. HALSTED ST., CHICAGO, IL
Confronta XCUR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.20 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.30 | 294.58M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
4.89 | 217.03M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
0.7228 | 0 | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
46.39 | 0 | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-12-13 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-12-18 | Iniziato | BMO Capital Markets | Outperform |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
Exicure Inc Borsa (XCUR) Ultime notizie
Trading the Move, Not the Narrative: (XCUR) Edition - news.stocktradersdaily.com
Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know - ts2.tech
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Promising Biotech Stocks To Keep An Eye OnDecember 9th - MarketBeat
Exicure stock soars 40% after stem cell drug helps most patients hit phase 2 goal — traders call it 'cheap' at current levels - MSN
Sangsangin investment sells Exicure (XCUR) shares worth $3.77 million By Investing.com - Investing.com Nigeria
Morning Market Movers: ASPC, ENVB, AFJK, JXG See Big Swings - RTTNews
Exicure’s Stunning Rise: What’s Fueling It? - StocksToTrade
Exicure Shares Surge 41% On Promising Phase 2 Data For Multiple Myeloma Drug - Nasdaq
Exicure Stock Soars 40% After Stem Cell Drug Helps Most Patients Hit Phase 2 Goal — Traders Call It ‘Cheap’ At Current Levels - Stocktwits
Exicure’s Risky Bet On Stem Cell Mobilization Pays Early Dividends - Finimize
Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial - Benzinga
Top Gainers on the US Stock Market Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and More Surge as Fed Meeting Looms - ts2.tech
Exicure (XCUR) Stock: Biotech Soars on Promising Cancer Drug Data - parameter.io
ASH: Exicure rebounds with phase 2 win, seeing 90% blood cell mobilization in myeloma - Fierce Biotech
Dow Surges Over 100 Points; Campbell's Posts Upbeat Earnings - Benzinga
This BlackRock stock just rocketed 70% - Finbold
Exicure (XCUR) Stock: Biotech Shares Surge 140% on Cancer Drug Breakthrough - Blockonomi
Exicure Inc.: Is It a Bet Worth Taking? - timothysykes.com
Exicure Inc (XCUR) expanding its growth trajectory ahead - setenews.com
Pre Market Movers: XCUR, VOR, MTVA Set The Path - RTTNews
Morning Market Movers: ATMC, XCUR, VOR, ATMV See Big Swings - RTTNews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Exicure Soars On Burixafor Data In Multiple Myeloma Trial - Nasdaq
Exicure Inc. (XCUR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
After-Hours Gainers: Exicure Tops List With 72% Jump, Wave Life And Assembly Biosciences Advance - Nasdaq
Exicure reports positive Phase 2 results for multiple myeloma therapy By Investing.com - Investing.com Nigeria
Exicure (XCUR) Sees Positive Phase 2 Trial Results for Burixafor in Multiple Myeloma - GuruFocus
Exicure presents topline data from burixafor combination trial - TipRanks
Exicure stock soars after positive Phase 2 data for multiple myeloma drug - Investing.com
Exicure, Inc. Reports Positive Phase 2 Trial Results for Burixafor in Hematopoietic Progenitor Cell Mobilization in Multiple Myeloma Patients - Quiver Quantitative
Exicure, Inc. Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma At 2025 Ash Annual Meeting - marketscreener.com
Exicure reports positive Phase 2 results for multiple myeloma therapy - Investing.com
KOSDAQ firm The Technology buys Exicure Hitechron amid embezzlement probe, sparking insider trading suspicionsCHOSUNBIZ - Chosunbiz
Exicure Inc Trading Resumes - MSN
What analysts say about Exicure Inc stockPrice Action Analysis & Use Time as Your Investing Ally - earlytimes.in
Exicure Inc 2H0 Stock Analysis and ForecastMarket Sentiment Shifts & Free Exceptional Market Positioning - earlytimes.in
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Exicure Stock Surges 76%, With A 6-Day Winning Spree - Trefis
(XCUR) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
How Exicure Inc. (2H0) stock expands through international marketsGlobal Markets & Weekly Stock Breakout Alerts - Newser
How Exicure Inc. (2H0) stock correlates with oil marketsBond Market & AI Powered Market Trend Analysis - Newser
Will Exicure Inc. stock gain from strong economy2025 Retail Activity & Stepwise Trade Signal Implementation - Newser
How Exicure Inc. (2H0) stock compares with tech leadersJuly 2025 Earnings & Long Hold Capital Preservation Tips - Newser
How Exicure Inc. (2H0) stock compares with market leadersQuarterly Profit Report & Growth Focused Entry Reports - Newser
Should I buy Exicure Inc. (2H0) stock before earnings seasonJuly 2025 EndofMonth & Weekly Top Gainers Alerts - Newser
Can Exicure Inc. (2H0) stock test all time highsSell Signal & Safe Entry Trade Reports - Newser
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Total assets of Exicure, Inc. – SWB:2H0 - TradingView
Exicure Redeems Convertible Bonds for Liquidity - MSN
Will Kanishk Steel Industries Limited Stock Continue to Outperform in YEARInsider Buying Signals & Free Tremendous Portfolio Expansion - earlytimes.in
Exicure Inc Azioni (XCUR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Exicure Inc Azioni (XCUR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HiTron Systems Inc. | 10% Owner |
Dec 26 '24 |
Buy |
3.00 |
2,900,000 |
8,700,000 |
3,333,333 |
0.42%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):